GrayMatters Health

GrayMatters Health is an Israeli neurotechnology company specializing in closed-loop neuromodulation, headquartered in Tel Aviv. The company developed Prism, a prescription digital therapeutic designed to treat post-traumatic stress disorder through EEG-guided neurofeedback. Prism works by monitoring a patient's real-time brain signals and training them to voluntarily self-regulate activity in the amygdala, the brain region central to fear and emotional processing. This closed-loop approach continuously adapts feedback based on live neural data, distinguishing it from conventional static therapeutic modalities. The result is a highly personalized, biomarker-driven intervention that operates at the level of the underlying neurobiology of PTSD.

GrayMatters Health has secured $20 million in Series B funding, reflecting growing investor confidence in its clinical and commercial trajectory. The company has advanced Prism through rigorous clinical evaluation, with studies demonstrating that patients can achieve meaningful, measurable changes in amygdala regulation following structured treatment sessions. PTSD represents a condition with significant unmet need, affecting millions globally and carrying high rates of treatment resistance to existing pharmacological and psychotherapy options. GrayMatters Health is positioning Prism as a non-invasive, software-based alternative that can complement or reduce reliance on traditional treatment pathways. Its regulatory and clinical development work reflects a commitment to meeting the evidentiary standards required for prescription digital therapeutics in major healthcare markets.

GrayMatters Health represents a meaningful advance in the broader movement toward neurobiologically targeted, personalized mental health treatment. By grounding its therapeutic in objective EEG biomarkers rather than subjective symptom reporting alone, the company exemplifies a more rigorous and mechanistic approach to psychiatric care. Its closed-loop architecture also signals where the neuromodulation field is heading, away from open-loop, one-size-fits-all stimulation and toward systems that respond dynamically to individual brain states in real time. For the neurotech industry, GrayMatters Health demonstrates that non-invasive digital tools can engage the central nervous system with meaningful clinical specificity. As mental health remains one of the largest and most underserved areas in global healthcare, the company's work carries implications well beyond PTSD and into the future of brain-based therapeutics broadly.